About OncoMed Pharmaceuticals (NASDAQ:OMED)
OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell (CSC) and immuno-oncology therapeutics. The company's product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand. The company has strategic alliances with GlaxoSmithKline LLC to develop and commercialize antibody therapeutics targeting the Notch signaling pathway; Bayer Pharma AG for biologic and small molecule therapeutics targeting the Wnt signaling pathway; and Celgene Corporation for anti-CSC product candidates. The company was founded in 2004 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OMED
CUSIPN/A
Phone650-995-8200
Debt
Debt-to-Equity RatioN/A
Current Ratio1.13%
Quick Ratio1.13%
Price-To-Earnings
Trailing P/E Ratio-2.80
Forward P/E Ratio-3.14
P/E GrowthN/A
Sales & Book Value
Annual Sales$38.15 million
Price / Sales3.02
Cash FlowN/A
Price / CashN/A
Book Value($1.28) per share
Price / Book-2.35
Profitability
EPS (Most Recent Fiscal Year)($1.04)
Net Income$-39,060,000.00
Net Margins-102.38%
Return on EquityN/A
Return on Assets-29.09%
Miscellaneous
Employees56
Outstanding Shares38,260,000
OncoMed Pharmaceuticals (NASDAQ:OMED) Frequently Asked Questions
What is OncoMed Pharmaceuticals' stock symbol?
OncoMed Pharmaceuticals trades on the NASDAQ under the ticker symbol "OMED."
How were OncoMed Pharmaceuticals' earnings last quarter?
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) released its quarterly earnings data on Thursday, March, 8th. The biopharmaceutical company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.59. The biopharmaceutical company had revenue of $20.64 million for the quarter, compared to the consensus estimate of $5.10 million. View OncoMed Pharmaceuticals' Earnings History.
When is OncoMed Pharmaceuticals' next earnings date?
What price target have analysts set for OMED?
5 analysts have issued 12-month target prices for OncoMed Pharmaceuticals' shares. Their forecasts range from $3.00 to $6.00. On average, they expect OncoMed Pharmaceuticals' stock price to reach $4.60 in the next twelve months. View Analyst Ratings for OncoMed Pharmaceuticals.
Who are some of OncoMed Pharmaceuticals' key competitors?
Some companies that are related to OncoMed Pharmaceuticals include Sienna Biopharmaceuticals (SNNA), Cara Therapeutics (CARA), Syros Pharmaceuticals (SYRS), Cytokinetics (CYTK), Kala Pharmaceuticals (KALA), GTX (GTXI), Albireo (ALBO), Clearside Biomedical (CLSD), Dermira (DERM), Corbus Pharmaceuticals (CRBP), Corium International (CORI), Mersana Therapeutics (MRSN), Unum Therapeutics (UMRX), Strongbridge Biopharma (SBBP) and Merus (MRUS).
Who are OncoMed Pharmaceuticals' key executives?
OncoMed Pharmaceuticals' management team includes the folowing people:
- Mr. Perry A. Karsen, Exec. Chairman (Age 63)
- Dr. John A. Lewicki, Pres (Age 66)
- Dr. Austin Gurney Ph.D., Chief Scientific Officer & Sr. VP (Age 54)
- Michelle Corral, Sr. Director of Investor Relations and Corp. Communications
- Dr. Alicia J. Hager J.D., Ph.D., Sr. VP and Gen. Counsel (Age 48)
Has OncoMed Pharmaceuticals been receiving favorable news coverage?
Media stories about OMED stock have been trending positive this week, according to Accern. The research firm rates the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. OncoMed Pharmaceuticals earned a media sentiment score of 0.39 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 47.17 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of OncoMed Pharmaceuticals?
Shares of OMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OncoMed Pharmaceuticals' stock price today?
One share of OMED stock can currently be purchased for approximately $3.01.
How big of a company is OncoMed Pharmaceuticals?
OncoMed Pharmaceuticals has a market capitalization of $102.15 million and generates $38.15 million in revenue each year. The biopharmaceutical company earns $-39,060,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. OncoMed Pharmaceuticals employs 56 workers across the globe.
How can I contact OncoMed Pharmaceuticals?
OncoMed Pharmaceuticals' mailing address is 800 Chesapeake Drive, Redwood City CA, 94063. The biopharmaceutical company can be reached via phone at 650-995-8200 or via email at [email protected]
MarketBeat Community Rating for OncoMed Pharmaceuticals (OMED)
MarketBeat's community ratings are surveys of what our community members think about OncoMed Pharmaceuticals and other stocks. Vote "Outperform" if you believe OMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
OncoMed Pharmaceuticals (NASDAQ:OMED) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for OncoMed Pharmaceuticals in the last 12 months. Their average twelve-month price target is $4.60, suggesting that the stock has a possible upside of 52.82%. The high price target for OMED is $6.00 and the low price target for OMED is $3.00. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.20 | 2.13 | 2.25 | 2.25 |
| Ratings Breakdown: | 0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
7 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.60 | $5.5714 | $6.00 | $6.00 |
| Price Target Upside: | 52.82% upside | 80.89% upside | 50.75% upside | 37.30% upside |
OncoMed Pharmaceuticals (NASDAQ:OMED) Consensus Price Target History
OncoMed Pharmaceuticals (NASDAQ:OMED) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
OncoMed Pharmaceuticals (NASDAQ:OMED) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
OncoMed Pharmaceuticals (NASDAQ OMED) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 32.80%
Institutional Ownership Percentage: 53.62%
OncoMed Pharmaceuticals (NASDAQ OMED) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/10/2017 | Alicia J Hager | SVP | Sell | 1,248 | $4.24 | $5,291.52 | |  |
| 10/10/2017 | Paul J Hastings | CEO | Sell | 1,398 | $4.24 | $5,927.52 | | |
| 6/5/2017 | Perry A Karsen | Director | Buy | 10,000 | $3.46 | $34,600.00 | 10,000 | |
| 5/26/2017 | Jonathan D Root | Director | Sell | 13,880 | $3.71 | $51,494.80 | 121,020 | |
| 5/25/2017 | Jack W Lasersohn | Director | Buy | 34,614 | $3.37 | $116,649.18 | 185,709 | |
| 5/23/2017 | Jack W Lasersohn | Director | Buy | 20,000 | $3.55 | $71,000.00 | 151,095 | |
| 5/19/2017 | Jonathan D Root | Director | Sell | 7,487 | $3.70 | $27,701.90 | 121,020 | |
| 5/16/2017 | Jack W Lasersohn | Director | Buy | 23,507 | $3.49 | $82,039.43 | 131,095 | |
| 4/4/2017 | Alicia J. Hager | SVP | Sell | 4,316 | $9.06 | $39,102.96 | | |
| 4/4/2017 | Paul J. Hastings | CEO | Sell | 6,473 | $9.06 | $58,645.38 | | |
| 4/4/2017 | Sunil Patel | Insider | Sell | 5,754 | $9.06 | $52,131.24 | | |
| 1/6/2017 | Paul J. Hastings | CEO | Sell | 42,738 | $8.34 | $356,434.92 | | |
| 1/3/2017 | John A. Lewicki | EVP | Sell | 9,175 | $7.63 | $70,005.25 | | |
| 1/3/2017 | Timothy Hoey | SVP | Sell | 12,763 | $7.64 | $97,509.32 | | |
| 1/11/2016 | Jakob Dupont | SVP | Sell | 2,500 | $20.01 | $50,025.00 | 20,642 | |
| 1/7/2016 | Alicia J. Hager | VP | Sell | 1,623 | $22.28 | $36,160.44 | 13,377 | |
| 1/7/2016 | John A. Lewicki | EVP | Sell | 2,162 | $22.28 | $48,169.36 | 17,838 | |
| 1/6/2016 | Paul J. Hastings | CEO | Sell | 2,412 | $22.28 | $53,739.36 | 22,025 | |
| 11/27/2015 | Alicia J. Hager | VP | Sell | 1,800 | $23.14 | $41,652.00 | 15,000 | |
| 10/27/2015 | Alicia J. Hager | VP | Sell | 5,400 | $21.00 | $113,400.00 | 15,000 | |
| 10/26/2015 | Austin Gurney | Insider | Sell | 14,000 | $20.00 | $280,000.00 | 35,419 | |
| 10/26/2015 | Jakob Dupont | SVP | Sell | 5,000 | $20.00 | $100,000.00 | 22,804 | |
| 9/30/2015 | Jack W. Lasersohn | Director | Buy | 11,210 | $16.01 | $179,472.10 | 46,560 | |
| 9/29/2015 | Jack W. Lasersohn | Director | Buy | 3,140 | $14.15 | $44,431.00 | 35,350 | |
| 9/28/2015 | Jack W. Lasersohn | Director | Buy | 10,000 | $14.74 | $147,400.00 | 35,350 | |
| 7/10/2015 | Jakob Dupont | SVP | Sell | 2,500 | $20.13 | $50,325.00 | | |
| 7/6/2015 | Jakob Dupont | SVP | Sell | 2,500 | $21.22 | $53,050.00 | | |
| 6/29/2015 | Alicia J Hager | VP | Sell | 1,800 | $22.67 | $40,806.00 | | |
| 6/22/2015 | Timothy Hoey | SVP | Sell | 5,000 | $26.07 | $130,350.00 | | |
| 6/16/2015 | John A Lewicki | EVP | Sell | 17,000 | $25.07 | $426,190.00 | | |
| 6/15/2015 | John A Lewicki | EVP | Sell | 8,500 | $24.92 | $211,820.00 | | |
| 5/27/2015 | Alicia J Hager | VP | Sell | 1,800 | $23.07 | $41,526.00 | | |
| 5/18/2015 | Austin Gurney | Insider | Sell | 4,000 | $22.48 | $89,920.00 | | |
| 4/27/2015 | Alicia J Hager | VP | Sell | 1,800 | $25.65 | $46,170.00 | | |
| 4/27/2015 | Timothy Hoey | SVP | Sell | 6,887 | $25.65 | $176,651.55 | | |
| 4/17/2015 | Austin Gurney | Insider | Sell | 4,000 | $25.51 | $102,040.00 | | |
| 4/10/2015 | Jakob Dupont | SVP | Sell | 1,500 | $26.51 | $39,765.00 | | |
| 4/2/2015 | John A Lewicki | EVP | Sell | 17,000 | $25.28 | $429,760.00 | | |
| 3/20/2015 | Sunil Patel | Insider | Sell | 18,000 | $27.76 | $499,680.00 | | |
| 3/17/2015 | Austin Gurney | Insider | Sell | 4,000 | $27.37 | $109,480.00 | | |
| 2/5/2015 | Timothy Hoey | SVP | Sell | 7,500 | $22.83 | $171,225.00 | | |
| 2/2/2015 | John A Lewicki | EVP | Sell | 4,000 | $22.49 | $89,960.00 | | |
| 1/20/2015 | Austin Gurney | Insider | Sell | 4,000 | $22.87 | $91,480.00 | | |
| 1/12/2015 | Jakob Dupont | SVP | Sell | 1,500 | $25.89 | $38,835.00 | | |
| 1/5/2015 | Jakob Dupont | SVP | Sell | 7,500 | $23.00 | $172,500.00 | | |
| 1/2/2015 | John A Lewicki | EVP | Sell | 4,000 | $22.10 | $88,400.00 | | |
| 12/31/2014 | Denise Pollard-Knight | Director | Sell | 3,799 | $21.66 | $82,286.34 | | |
| 12/30/2014 | Denise Pollard-Knight | Director | Sell | 17,607 | $21.63 | $380,839.41 | | |
| 12/18/2014 | Jonathan D Root | Director | Sell | 13,052 | $21.05 | $274,744.60 | | |
| 12/17/2014 | Austin Gurney | Insider | Sell | 4,000 | $20.00 | $80,000.00 | | |
| 12/10/2014 | Denise Pollard-Knight | Director | Sell | 32,940 | $21.78 | $717,433.20 | | |
| 12/9/2014 | Denise Pollard-Knight | Director | Sell | 23,273 | $21.78 | $506,885.94 | | |
| 12/8/2014 | Denise Pollard-Knight | Director | Sell | 1,727 | $21.68 | $37,441.36 | | |
| 12/5/2014 | Denise Pollard-Knight | Director | Sell | 25,000 | $21.60 | $540,000.00 | | |
| 12/1/2014 | John A Lewicki | EVP | Sell | 4,000 | $21.19 | $84,760.00 | | |
| 11/5/2014 | Timothy Hoey | SVP | Sell | 2,500 | $19.51 | $48,775.00 | | |
| 10/29/2014 | Paul J Hastings | CEO | Sell | 16,769 | $21.99 | $368,750.31 | | |
| 10/2/2014 | Austin Gurney | Insider | Sell | 4,000 | $20.00 | $80,000.00 | | |
| 10/2/2014 | John A Lewicki | EVP | Sell | 5,809 | $20.00 | $116,180.00 | | |
| 9/4/2014 | Jack W Lasersohn | Director | Buy | 3,170 | $18.35 | $58,169.50 | | |
| 9/3/2014 | Jack W Lasersohn | Director | Buy | 3,000 | $18.40 | $55,200.00 | | |
| 9/2/2014 | John A Lewicki | EVP | Sell | 2,191 | $20.01 | $43,841.91 | | |
| 8/22/2014 | Austin Gurney | Insider | Sell | 4,000 | $20.00 | $80,000.00 | | |
| 8/21/2014 | Deepika Pakianathan | Director | Buy | 80,203 | $18.98 | $1,522,252.94 | | |
| 8/15/2014 | Jack W Lasersohn | Director | Buy | 1,045 | $17.00 | $17,765.00 | | |
| 8/5/2014 | Timothy Hoey | SVP | Sell | 2,500 | $21.66 | $54,150.00 | | |
| 8/1/2014 | John A Lewicki | EVP | Sell | 4,000 | $20.98 | $83,920.00 | | |
| 7/29/2014 | Paul J Hastings | CEO | Sell | 16,770 | $22.11 | $370,784.70 | | |
| 7/23/2014 | Jakob Dupont | SVP | Sell | 1,500 | $23.00 | $34,500.00 | | |
| 7/17/2014 | Austin Gurney | Insider | Sell | 4,000 | $20.46 | $81,840.00 | | |
| 7/1/2014 | John A Lewicki | EVP | Sell | 4,000 | $23.86 | $95,440.00 | | |
| 6/30/2014 | Denise Pollard-Knight | Director | Sell | 11,485 | $23.59 | $270,931.15 | | |
| 6/26/2014 | Jakob Dupont | SVP | Sell | 1,500 | $23.00 | $34,500.00 | | |
| 6/25/2014 | Denise Pollard-Knight | Director | Sell | 3,252 | $23.56 | $76,617.12 | | |
| 6/24/2014 | Denise Pollard-Knight | Director | Sell | 64,561 | $24.08 | $1,554,628.88 | | |
| 6/17/2014 | Austin Gurney | Insider | Sell | 4,000 | $24.99 | $99,960.00 | | |
| 6/16/2014 | John A Lewicki | EVP | Sell | 4,000 | $24.59 | $98,360.00 | | |
| 6/10/2014 | Presidio Management Group Viii | Major Shareholder | Sell | 13,052 | $24.57 | $320,687.64 | | |
| 5/12/2014 | Presidio Management Group Viii | major shareholder | Sell | 46,327 | $21.99 | $1,018,730.73 | | |
| 7/23/2013 | Denise Pollard-Knight | Director | Buy | 58,824 | $17.00 | $1,000,008.00 | | |
| 7/23/2013 | Presidio Management Group Viii | Major Shareholder | Buy | 158,823 | $17.00 | $2,699,991.00 | | |
(Data available from 1/1/2013 forward)
OncoMed Pharmaceuticals (NASDAQ OMED) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Zacks: Analysts Expect OncoMed Pharmaceuticals, Inc. (OMED) Will Post Quarterly Sales of $6.51 Million
www.americanbankingnews.com - April 23 at 4:14 AM |
| -$0.24 EPS Expected for OncoMed Pharmaceuticals, Inc. (OMED) This Quarter
www.americanbankingnews.com - April 21 at 11:12 AM |
| OncoMed Pharmaceuticals (OMED) Given a $5.00 Price Target by Piper Jaffray Analysts
www.americanbankingnews.com - April 19 at 12:16 PM |
 | OncoMed Pharma (OMED) Presents Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at AACR
www.streetinsider.com - April 19 at 10:07 AM |
| OncoMed Pharmaceuticals, Inc. (OMED) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 19 at 9:13 AM |
 | OncoMed Presents Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 18 at 10:06 AM |
| OncoMed to Present Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 9 at 10:21 AM |
| $6.51 Million in Sales Expected for OncoMed Pharmaceuticals, Inc. (OMED) This Quarter
www.americanbankingnews.com - April 6 at 3:42 AM |
| -$0.24 Earnings Per Share Expected for OncoMed Pharmaceuticals, Inc. (OMED) This Quarter
www.americanbankingnews.com - April 4 at 11:46 AM |
| Oncomed Pharmaceuticals (OMED) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - April 1 at 11:52 AM |
| Oncomed Pharmaceuticals (OMED) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - March 31 at 9:24 PM |
| Can The Uptrend Continue for OncoMed Pharmaceuticals (OMED)?
finance.yahoo.com - March 27 at 4:11 PM |
| Oncomed Pharmaceuticals Inc (OMED) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 25 at 7:58 AM |
| $6.51 Million in Sales Expected for Oncomed Pharmaceuticals Inc (OMED) This Quarter
www.americanbankingnews.com - March 20 at 5:52 AM |
 | BRIEF-OncoMed Announces Appointment Of John Lewicki As CEO
www.reuters.com - March 19 at 4:14 PM |
| OncoMed Announces Appointment of John Lewicki, PhD, as President, Chief Executive Officer and a member of the Board of Directors
finance.yahoo.com - March 19 at 10:36 AM |
| Oncomed Pharmaceuticals (OMED) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 17 at 11:46 PM |
| OncoMed Pharmaceuticals Inc (NASDAQ:OMED): What Are The Future Prospects?
finance.yahoo.com - March 16 at 4:13 PM |
| Catalyst Pharmaceuticals Inc (CPRX) and Achillion Pharmaceuticals, Inc. (ACHN) Among Five Cheap Healthcare Stocks To Buy Now
finance.yahoo.com - March 14 at 4:08 PM |
| HC Wainwright Reaffirms Hold Rating for Oncomed Pharmaceuticals (OMED)
www.americanbankingnews.com - March 9 at 9:04 PM |
| Oncomed Pharmaceuticals (OMED) Posts Earnings Results, Beats Expectations By $0.59 EPS
www.americanbankingnews.com - March 9 at 4:27 PM |
| OncoMed Announces Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights
finance.yahoo.com - March 9 at 11:54 AM |
| OncoMed tops Street 4Q forecasts
finance.yahoo.com - March 9 at 11:54 AM |
| When Can We Expect A Profit From OncoMed Pharmaceuticals Inc (NASDAQ:OMED)?
finance.yahoo.com - March 9 at 11:54 AM |
| OncoMed Pharmaceuticals Q4 Earnings Preview
finance.yahoo.com - March 8 at 4:12 PM |
| Has OncoMed Pharmaceuticals Inc (NASDAQ:OMED) Improved Earnings Growth In Recent Times?
finance.yahoo.com - March 7 at 4:04 PM |
 | Partner Therapeutics (PTx) Announces the Appointment of Ellen Hukkelhoven Ph.D. and Terry Gould to its Board of Directors
www.bizjournals.com - March 7 at 10:52 AM |
| Brokerages Expect Oncomed Pharmaceuticals Inc (OMED) Will Post Quarterly Sales of $5.10 Million
www.americanbankingnews.com - March 3 at 1:22 PM |
| Oncomed Pharmaceuticals Inc (OMED) Expected to Post Earnings of -$0.31 Per Share
www.americanbankingnews.com - March 1 at 11:45 AM |
| Oncomed Pharmaceuticals (OMED) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - March 1 at 2:08 AM |
| Oncomed Pharmaceuticals Inc (OMED) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 28 at 11:57 AM |
| Oncomed Pharmaceuticals' (OMED) "Neutral" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - February 24 at 3:32 PM |
| OncoMed Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights on March 8th, 2018
finance.yahoo.com - February 23 at 10:19 AM |
| Why You Need To Look At This Factor Before Buying OncoMed Pharmaceuticals Inc (NASDAQ:OMED)
finance.yahoo.com - February 21 at 10:54 AM |
| Zacks: Analysts Anticipate Oncomed Pharmaceuticals Inc (OMED) Will Announce Quarterly Sales of $5.10 Million
www.americanbankingnews.com - February 14 at 5:04 AM |
| Oncomed Pharmaceuticals (OMED) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - February 14 at 2:56 AM |
| Organovo (ONVO) and Oncomed Pharmaceuticals (OMED) Critical Review
www.americanbankingnews.com - February 11 at 3:22 AM |
| Oncomed Pharmaceuticals Inc (OMED) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - February 3 at 12:01 PM |
| What’s Installed For OncoMed Pharmaceuticals Inc (NASDAQ:OMED)?
finance.yahoo.com - January 30 at 5:55 AM |
| Oncomed Pharmaceuticals Inc (OMED) Expected to Post Quarterly Sales of $5.10 Million
www.americanbankingnews.com - January 28 at 2:58 AM |
| Oncomed Pharmaceuticals Inc (OMED) Expected to Announce Earnings of -$0.31 Per Share
www.americanbankingnews.com - January 26 at 5:20 PM |
| Oncomed Pharmaceuticals (OMED) versus Sorrento Tech (ROKA) Head-To-Head Contrast
www.americanbankingnews.com - January 22 at 11:32 AM |
| What Should You Know About OncoMed Pharmaceuticals Inc’s (NASDAQ:OMED) Earnings Trajectory?
finance.yahoo.com - January 11 at 10:38 AM |
| Analysts Anticipate Oncomed Pharmaceuticals Inc (OMED) to Post -$0.31 EPS
www.americanbankingnews.com - January 9 at 3:42 PM |
| Oncomed Pharmaceuticals Inc (OMED) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - January 9 at 9:58 AM |
| SunTrust Banks Comments on Oncomed Pharmaceuticals Inc's FY2022 Earnings (OMED)
www.americanbankingnews.com - January 8 at 8:10 PM |
| Newman Ferrara LLP Announces Corporate Governance Investigation of OncoMed Pharmaceuticals Inc. - OMED
finance.yahoo.com - January 8 at 4:46 PM |
| Cantor Fitzgerald Analysts Give Oncomed Pharmaceuticals (OMED) a $6.00 Price Target
www.americanbankingnews.com - January 7 at 12:44 AM |
| Oncomed Pharmaceuticals (OMED) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - January 6 at 7:02 AM |
| BRIEF-Oncomed Says Chief Executive Officer Paul Hastings Has Resigned
www.reuters.com - January 4 at 4:40 PM |
OncoMed Pharmaceuticals (NASDAQ:OMED) SEC Filings
This page is loading this company's SEC Filings. Please wait...
OncoMed Pharmaceuticals (NASDAQ:OMED) Income Statement, Balance Sheet and Cash Flow Statement
OncoMed Pharmaceuticals (NASDAQ OMED) Stock Chart for Thursday, April, 26, 2018
Loading chart…
